Home The Word Brain My Amedeo FAQ Privacy About   

2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.

  Prostate Cancer

  Free Subscription


1 AJR Am J Roentgenol
2 BMC Urol
1 Br J Cancer
1 Cancer
2 Cancer Imaging
1 Clin Med Insights Oncol
1 Eur Radiol
1 Int J Urol
3 J Nucl Med
3 J Urol
1 PLoS One
3 Prostate
1 Urol Int

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

    Editorial Comment: Similar Upgrade and Downgrade Rates Between PI-RADS Version 2.0 and Version 2.1.
    AJR Am J Roentgenol. 2024;222:e2330325.

    BMC Urol

  2. ZHOU C, Zhang X, Ma H, Zhou Y, et al
    USP54 is a potential therapeutic target in castration-resistant prostate cancer.
    BMC Urol. 2024;24:32.
    PubMed         Abstract available

  3. WINDISCH P, Becker I, Tang H, Schroder C, et al
    Converting between the International Prostate Symptom Score (IPSS) and the Expanded Prostate Cancer Index Composite (EPIC) urinary subscales: modeling and external validation.
    BMC Urol. 2024;24:28.
    PubMed         Abstract available

    Br J Cancer

  4. O'MALLEY DE, Raspin K, Melton PE, Burdon KP, et al
    Acquired copy number variation in prostate tumours: a review of common somatic copy number alterations, how they are formed and their clinical utility.
    Br J Cancer. 2024;130:347-357.
    PubMed         Abstract available


  5. RUAN Y, Heer E, Warkentin MT, Jarada TN, et al
    The association between neighborhood-level income and cancer stage at diagnosis and survival in Alberta.
    Cancer. 2024;130:563-575.
    PubMed         Abstract available

    Cancer Imaging

  6. HU C, Qiao X, Hu C, Cao C, et al
    The practical clinical role of machine learning models with different algorithms in predicting prostate cancer local recurrence after radical prostatectomy.
    Cancer Imaging. 2024;24:23.
    PubMed         Abstract available

  7. GUERRA A, Orton MR, Wang H, Konidari M, et al
    Clinical application of machine learning models in patients with prostate cancer before prostatectomy.
    Cancer Imaging. 2024;24:24.
    PubMed         Abstract available

    Clin Med Insights Oncol

  8. BENJAMIN DJ, Rezazadeh Kalebasty A
    Characterization and Survival Benefit of Drug Approvals for Metastatic Prostate Cancer, 2004 to 2022.
    Clin Med Insights Oncol. 2024;18:11795549241227413.

    Eur Radiol

  9. PADHANI AR, Godtman RA, Schoots IG
    Key learning on the promise and limitations of MRI in prostate cancer screening.
    Eur Radiol. 2024 Feb 5. doi: 10.1007/s00330-024-10626.
    PubMed         Abstract available

    Int J Urol

  10. HIYAMA Y
    Editorial Comment: Proctoscopy following transrectal prostate biopsy can control rectal bleeding after prostate biopsy.
    Int J Urol. 2024;31:143.

    J Nucl Med

  11. KUMAR S, Crumbaker M, Emmett L
    Reply: Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:333-334.

  12. RAHBAR K, Boegemann M
    The Imperative for Comparative Studies in Nuclear Medicine: Elevating (177)Lu-PSMA-617 in the Treatment Paradigm for mCRPC.
    J Nucl Med. 2024 Jan 4:jnumed.123.266952. doi: 10.2967/jnumed.123.266952.

  13. ASKARI E, Harsini S
    Unraveling the Hypocalcemic Response to (177)Lu-Prostate-Specific Membrane Antigen Therapy.
    J Nucl Med. 2024;65:332-333.

    J Urol

  14. MANNAS MP, Deng FM, Ion-Margineanu A, Jones D, et al
    Stimulated Raman Histology Interpretation by Artificial Intelligence Provides Near-Real-Time Pathologic Feedback for Unprocessed Prostate Biopsies.
    J Urol. 2024;211:384-391.
    PubMed         Abstract available

  15. FLORES JM, Vertosick E, Jenkins LC, Cooper J, et al
    Do Phosphodiesterase Type 5 Inhibitors Increase the Risk of Biochemical Recurrence After Radical Prostatectomy?
    J Urol. 2024;211:400-406.
    PubMed         Abstract available

  16. LOEB S, Sanchez Nolasco T, Byrne N, Allen L, et al
    Representation Matters: Trust in Digital Health Information Among Black Patients With Prostate Cancer.
    J Urol. 2024;211:376-383.
    PubMed         Abstract available

    PLoS One

  17. WU H, Wu Y, He P, Liang J, et al
    A meta-analysis for the diagnostic accuracy of SelectMDx in prostate cancer.
    PLoS One. 2024;19:e0285745.
    PubMed         Abstract available


  18. ULYS A, Jankevicus F, Jievaltas M, Venckus R, et al
    Efficacy, tolerability, and safety of teverelix DP in patients with advanced prostate cancer: A multicenter, open-label, phase 2 trial.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24674.
    PubMed         Abstract available

  19. HOYOS JA, Londono DR, Hoyos AG, Reyes EC, et al
    Impact of presentation timing in metastatic hormone-sensitive prostate cancer: Characterization of patients and identification of prognostic factors.
    Prostate. 2024 Feb 4. doi: 10.1002/pros.24672.
    PubMed         Abstract available

  20. LUO LS, Huang J, Luan HH, Mubarik S, et al
    Estimating disparities of prostate cancer burden and its attributable risk factors for males across the BRICS-plus, 1990-2019: A comparable study of key nations with emerging economies.
    Prostate. 2024 Feb 8. doi: 10.1002/pros.24673.
    PubMed         Abstract available

    Urol Int

  21. WU S, Feldman AS, Lin SX, Kim MM, et al
    Estimated Prostate Volume by Semiautomatic Segmentation of MRI Is More Accurately Correlated with Radical Prostatectomy Specimen Weight than the Volume Calculated by Ellipsoid Formula.
    Urol Int. 2024;108:35-41.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.